Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

We review the physiology and pharmacology of two atypical fibroblast growth factors (FGFs)-FGF15/19 and FGF21-that can function as hormones. Both FGF15/19 and FGF21 act on multiple tissues to coordinate carbohydrate and lipid metabolism in response to nutritional status. Whereas FGF15/19 is secreted from the small intestine in response to feeding and has insulin-like actions, FGF21 is secreted from the liver in response to extended fasting and has glucagon-like effects. FGF21 also acts in an autocrine fashion in several tissues, including adipose. The pharmacological actions of FGF15/19 and FGF21 make them attractive drug candidates for treating metabolic disease.

[1]  S. Kliewer,et al.  Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones , 2012, Cell.

[2]  D. Gouma,et al.  The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract , 2012, Hepatology.

[3]  N. Chinookoswong,et al.  Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. , 2012, Endocrinology.

[4]  K. Oishi,et al.  Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice. , 2011, Biochemical and biophysical research communications.

[5]  N. Harada,et al.  Paradoxical Regulation of Human FGF21 by Both Fasting and Feeding Signals: Is FGF21 a Nutritional Adaptation Factor? , 2011, PloS one.

[6]  Weiqing Wang,et al.  Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. , 2011, Diabetes research and clinical practice.

[7]  B. Spiegelman,et al.  Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. , 2011, Endocrinology.

[8]  S. Kliewer,et al.  FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. , 2011, Cell metabolism.

[9]  A. Zinsmeister,et al.  A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. , 2011, Gastroenterology.

[10]  S. Kliewer,et al.  FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.

[11]  A. Peterson,et al.  FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways , 2011, PloS one.

[12]  Lincoln D. Stein,et al.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.

[13]  W. Wurst,et al.  Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis. , 2011, Developmental biology.

[14]  F. Villarroya,et al.  Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue* , 2011, The Journal of Biological Chemistry.

[15]  A. Papavassiliou,et al.  Brown Adipose Tissue Responds to Cold and Adrenergic Stimulation by Induction of FGF21 , 2011, Molecular medicine.

[16]  M. Haluzík,et al.  Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. , 2011, Physiological research.

[17]  K. Xiang,et al.  Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. , 2010, Journal of hepatology.

[18]  S. Kliewer,et al.  Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. , 2010, Molecular endocrinology.

[19]  F. Kuipers,et al.  Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism , 2010, Hepatology.

[20]  B. Aktas,et al.  Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease , 2010, European journal of clinical investigation.

[21]  D. Wasserman,et al.  Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. , 2010, American journal of physiology. Endocrinology and metabolism.

[22]  C. Aguilar-Salinas,et al.  Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. , 2010, European journal of endocrinology.

[23]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[24]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[25]  B. Lemon,et al.  Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19) , 2010, Proceedings of the National Academy of Sciences.

[26]  Qing Yang,et al.  Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway , 2010, Proceedings of the National Academy of Sciences.

[27]  M. Schwartz,et al.  Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats , 2010, Diabetes.

[28]  F. Villarroya,et al.  Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. , 2010, Cell metabolism.

[29]  M. Fasshauer,et al.  Fibroblast Growth Factor 19 Serum Levels: Relation to Renal Function and Metabolic Parameters , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[30]  K. Nakao,et al.  Relevant use of Klotho in FGF19 subfamily signaling system in vivo , 2010, Proceedings of the National Academy of Sciences.

[31]  K. Oishi,et al.  FGF21 is dispensable for hypothermia induced by fasting in mice. , 2010, Neuro endocrinology letters.

[32]  A. Nowakowski,et al.  Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. , 2010, Endokrynologia Polska.

[33]  M. Goldstein,et al.  Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. , 2010, The Journal of clinical endocrinology and metabolism.

[34]  B. Lemon,et al.  FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation , 2009, The Journal of Biological Chemistry.

[35]  N. Chinookoswong,et al.  Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. , 2009, American journal of physiology. Endocrinology and metabolism.

[36]  Tracy Dew,et al.  A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  E. Fazio,et al.  Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. , 2009, Gastroenterology.

[38]  J. Flier,et al.  Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. , 2009, Endocrinology.

[39]  E. Maratos-Flier,et al.  A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. , 2009, American journal of physiology. Endocrinology and metabolism.

[40]  Y. Li,et al.  Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice , 2009, FEBS letters.

[41]  M. Konishi,et al.  Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. , 2009, Endocrinology.

[42]  J. Takeda,et al.  Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes , 2009, FEBS letters.

[43]  D. Wasserman,et al.  Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. , 2009, Endocrinology.

[44]  F. Karpe,et al.  Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. , 2009, The Journal of clinical endocrinology and metabolism.

[45]  M. Matoulek,et al.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.

[46]  B. Lemon,et al.  Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice , 2009, Proceedings of the National Academy of Sciences.

[47]  S. Kliewer,et al.  FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response , 2009, Proceedings of the National Academy of Sciences.

[48]  W. Mckeehan,et al.  Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis , 2009, Molecular carcinogenesis.

[49]  R. DeFronzo,et al.  Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.

[50]  Timothy D Veenstra,et al.  Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. , 2009, Genes & development.

[51]  D. Gouma,et al.  High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis , 2009, Hepatology.

[52]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[53]  Jason K. Kim,et al.  Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.

[54]  M. Kuro-o,et al.  Endocrine fibroblast growth factors as regulators of metabolic homeostasis , 2009, BioFactors.

[55]  S. Swoap,et al.  Norepinephrine Controls Both Torpor Initiation and Emergence via Distinct Mechanisms in the Mouse , 2008, PloS one.

[56]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[57]  K. Oishi,et al.  Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. , 2008, Endocrinology.

[58]  M. Haluzík,et al.  Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. , 2008, The Journal of clinical endocrinology and metabolism.

[59]  M. Eriksson,et al.  The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. , 2008, Cell metabolism.

[60]  Kenny K. Wong,et al.  Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States , 2008, Molecular Pharmacology.

[61]  I. Cobos,et al.  FGF15 promotes neurogenesis and opposes FGF8 function during neocortical development , 2008, Neural Development.

[62]  S. Kliewer,et al.  Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. , 2008, Cell metabolism.

[63]  D. Moore,et al.  Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation , 2008, Hepatology.

[64]  K. Hotzel,et al.  Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. , 2008, Cancer research.

[65]  P. Arner,et al.  FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity , 2008, FEBS letters.

[66]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[67]  J. D. Dunbar,et al.  FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho , 2008, Journal of cellular physiology.

[68]  Masashi Suzuki,et al.  betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. , 2008, Molecular endocrinology.

[69]  R. Carano,et al.  Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models , 2008, Oncogene.

[70]  D. Stejskal,et al.  Fibroblast growth factor‐19: Development, analytical characterization and clinical evaluation of a new ELISA test , 2008, Scandinavian journal of clinical and laboratory investigation.

[71]  G. Boden,et al.  Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[72]  S. Kliewer,et al.  Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007. , 2007, Journal of Lipid Research.

[73]  W. Pan,et al.  The fasting polypeptide FGF21 can enter brain from blood , 2007, Peptides.

[74]  S. Kliewer,et al.  FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption Published, JLR Papers in Press, September 6, 2007. , 2007, Journal of Lipid Research.

[75]  J. Flier,et al.  PPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo , 2007 .

[76]  L. Qiang,et al.  Identification of a Domain within Peroxisome Proliferator-Activated Receptor γ Regulating Expression of a Group of Genes Containing Fibroblast Growth Factor 21 That Are Selectively Repressed by SIRT1 in Adipocytes , 2007, Molecular and Cellular Biology.

[77]  B. Lemon,et al.  Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling* , 2007, Journal of Biological Chemistry.

[78]  W. Mckeehan,et al.  FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver , 2007, Diabetes.

[79]  S. Kliewer,et al.  Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21* , 2007, Journal of Biological Chemistry.

[80]  T. Lundåsen,et al.  PPARα is a key regulator of hepatic FGF21 , 2007 .

[81]  J. Flier,et al.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.

[82]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[83]  J. Ward,et al.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.

[84]  K. Rosenblatt,et al.  βKlotho is required for metabolic activity of fibroblast growth factor 21 , 2007, Proceedings of the National Academy of Sciences.

[85]  S. Kliewer,et al.  Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.

[86]  W. Wilcox,et al.  Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage , 2007, Pediatric Research.

[87]  Yun-Fei Chen,et al.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.

[88]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[89]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[90]  T. Lundåsen,et al.  Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man , 2006, Journal of internal medicine.

[91]  S. Kliewer,et al.  Identification of a hormonal basis for gallbladder filling , 2006, Nature Medicine.

[92]  H. Towle,et al.  ChREBP•Mlx Is the Principal Mediator of Glucose-induced Gene Expression in the Liver* , 2006, Journal of Biological Chemistry.

[93]  J. Gromada,et al.  Fibroblast Growth Factor-21 Improves Pancreatic β-Cell Function and Survival by Activation of Extracellular Signal–Regulated Kinase 1/2 and Akt Signaling Pathways , 2006, Diabetes.

[94]  Y. Deshaies,et al.  PPARγ agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control , 2006, Diabetologia.

[95]  K. Rosenblatt,et al.  Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.

[96]  D. Mangelsdorf,et al.  LXRS and FXR: the yin and yang of cholesterol and fat metabolism. , 2006, Annual review of physiology.

[97]  Michael R. Blackburn,et al.  Constant darkness is a circadian metabolic signal in mammals , 2006, Nature.

[98]  Xueying Lin,et al.  Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. , 2006, The Journal of clinical investigation.

[99]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[100]  Y. Nabeshima,et al.  Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. , 2005, The Journal of clinical investigation.

[101]  I. Talianidis,et al.  Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP , 2005, The EMBO journal.

[102]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[103]  W. Mckeehan,et al.  Independent Repression of Bile Acid Synthesis and Activation of c-Jun N-terminal Kinase (JNK) by Activated Hepatocyte Fibroblast Growth Factor Receptor 4 (FGFR4) and Bile Acids* , 2005, Journal of Biological Chemistry.

[104]  H. Ginsberg,et al.  Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus , 2005 .

[105]  G. Salen,et al.  Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.

[106]  M. Noshiro,et al.  Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats , 2004, Steroids.

[107]  R. Soriano,et al.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.

[108]  F. Geiser,et al.  Metabolic rate and body temperature reduction during hibernation and daily torpor. , 2004, Annual review of physiology.

[109]  M. Lowe,et al.  Pancreatic triacylglycerol lipase in a hibernating mammal. II. Cold-adapted function and differential expression. , 2003, Physiological genomics.

[110]  D. Russell.  The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.

[111]  F. Kuipers,et al.  Enterohepatic Circulation of Bile Salts in Farnesoid X Receptor-deficient Mice , 2003, Journal of Biological Chemistry.

[112]  S. Tilghman,et al.  Glyceroneogenesis and the Triglyceride/Fatty Acid Cycle* , 2003, Journal of Biological Chemistry.

[113]  P. Brûlet,et al.  Study of Fgf15 gene expression in developing mouse brain. , 2003, Gene expression patterns : GEP.

[114]  M. Katoh,et al.  Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human. , 2003, International journal of molecular medicine.

[115]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[116]  A. McMahon,et al.  A sonic hedgehog-dependent signaling relay regulates growth of diencephalic and mesencephalic primordia in the early mouse embryo. , 2002, Development.

[117]  D. Russell,et al.  Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. , 2002, Developmental cell.

[118]  M. Karin,et al.  Redundant pathways for negative feedback regulation of bile acid production. , 2002, Developmental cell.

[119]  G. Frantz,et al.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.

[120]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .

[121]  P. Brûlet,et al.  Analysis of Fgf15 expression pattern in the mouse neural tube , 2002, Brain Research Bulletin.

[122]  N. Mitro,et al.  The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. , 2001, The Journal of biological chemistry.

[123]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[124]  B. Ljung,et al.  Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. , 2001, Diabetes.

[125]  Y. Nabeshima,et al.  Molecular cloning and expression analyses of mouse βklotho, which encodes a novel Klotho family protein , 2000, Mechanisms of Development.

[126]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[127]  T Hashimoto,et al.  Defect in Peroxisome Proliferator-activated Receptor α-inducible Fatty Acid Oxidation Determines the Severity of Hepatic Steatosis in Response to Fasting* , 2000, The Journal of Biological Chemistry.

[128]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[129]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[130]  M. Konishi,et al.  Identification of a novel FGF, FGF-21, preferentially expressed in the liver. , 2000, Biochimica et biophysica acta.

[131]  C. Deng,et al.  Elevated Cholesterol Metabolism and Bile Acid Synthesis in Mice Lacking Membrane Tyrosine Kinase Receptor FGFR4* , 2000, The Journal of Biological Chemistry.

[132]  A. Goddard,et al.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. , 1999, Cytokine.

[133]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[134]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[135]  N. Itoh,et al.  Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. , 1999, Biochimica et biophysica acta.

[136]  J. Chiang.  Regulation of bile acid synthesis. , 1998, Frontiers in bioscience : a journal and virtual library.

[137]  J. Weiner,et al.  A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. , 1997, Development.

[138]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[139]  P. Hylemon,et al.  Regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat. , 1991, The Journal of biological chemistry.